Rischka, Lucas
Murgaš, Matej
Pichler, Verena
Vraka, Chrysoula
Rausch, Ivo
Winkler, Dietmar
Nics, Lukas
Rasul, Sazan
Silberbauer, Leo Robert
Reed, Murray Bruce
Godbersen, Godber Mathis
Unterholzner, Jakob
Handschuh, Patricia
Gryglewski, Gregor
Mindt, Thomas
Mitterhauser, Markus
Hahn, Andreas
Ametamey, Simon Mensah
Wadsak, Wolfgang
Lanzenberger, Rupert http://orcid.org/0000-0003-4641-9539
Hacker, Marcus
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030E-160403/1, 310030E-182872/1)
Austrian Science Fund (DOC 33-B27)
Österreichischen Akademie der Wissenschaften (DOC fellowship, DOC fellowship)
Article History
Received: 19 January 2022
Accepted: 17 August 2022
First Online: 26 August 2022
Declarations
:
: The study was approved by the Ethics Committee (ethics number: 1980/2018) of the Medical University of Vienna. Procedures were carried out in accordance with the Declaration of Helsinki.
: All subjects gave written informed consent after detailed explanation of the study procedure.
: Not applicable.
: S. M. Ametamey is co-inventor of the filed patent number US2017/0224852A1. R. Lanzenberger received travel grants and/or conference speaker honoraria within the last three years from Bruker BioSpin MR and support from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of the start-up company BM Health GmbH since 2019. D. Winkler received lecture fees/authorship honoraria within the last three years from Angelini, Lundbeck, MedMedia Verlag, and Medical Dialogue. Without relevance to this work, W. Wadsak received within the last 3 years research grants from ITM Medical Isotopes GmbH (Munich, Germany) and Scintomics (Fürstenfeldbruck, Germany). Without relevance to this work, M. Mitterhauser is scientific advisor for ROTOP Pharma GmbH. All other authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.